ClinicalTrials.gg
WithdrawnNCT06259201VNSUpdated Feb 13, 2026

Vagus Nerve Stimulator for Autism and Other Developmental Disorders

An interventional study of Vagus Nerve Stimulation in Autism Spectrum Disorder, Intellectual Disability and Autonomic Nervous System, sponsored by New York State Institute for Basic Research. Withdrawn at 2 sites in United States. Open to participants aged 12 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by New York State Institute for Basic Research · Not applicable, Interventional, and Treatment

How we know

Why this study was withdrawn
Investigator decided to terminate the study - no participant enrolled.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
12 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 773 studies in Autism Spectrum Disorder with a site in United States — 163 open to participants now, 203 under way, 9 of them phase 3. Autism Spectrum Disorder · United States.

Enrollment
639th of 658
0 · median 50
Started
2025
with 31 others
No phase
456 of 773
104 open now
Registered
616th of 773
by date

Among the 773 studies in Autism Spectrum Disorder with a site in United States, this one is the 639th largest by enrollment of the 658 interventional ones that give a count, is one of 32 that started in 2025, is one of 456 with no phase, and was the 616th registered.

Autism Spectrum Disorder

1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.

Browse Autism Spectrum Disorder studies →

Open to participants now

163 of the 773 studies in Autism Spectrum Disorder with a site in United States are open now. Recruiting first, the newest first:

158 more — sign in →

All 163 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 301 take children under 18; 92 take healthy volunteers.

This study: 12 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 773 studies in Autism Spectrum Disorder with a site in United States, or all of them as a file.
02

Study summary

The goal of this flexible single-subject design vagus nerve stimulation (VNS) study is to examine the behavioral, cognitive, and biorhythmic effects of VNS in children and adults with autism and developmental disabilities. The main aims are:

  • Pilot the creation of a profile for those who will respond to VNS with the long-term goal of designing clinical trials.
  • Examine the effects of VNS on a broad range of symptoms.

Participants will select between 1, 2, or 3 months of daily VNS treatment and complete study visits each month.

Read the detailed description

Intellectual and developmental disabilities (IDD) cover a wide variety of disorders. Although we know the causes of some of the disorders and some of them could even be prevented (e.g., lead exposure), most causes remain unknown. Without having a clear understanding of the causes, prevention is very difficult to achieve. Previous studies have shown abnormal autonomic nervous system (ANS) regulations in young children with autism spectrum disorder (ASD) and these abnormalities are also observed during sleep. ANS is the part of the nervous system that controls the unconscious bodily functions, such as breathing, heart beating, and digestion.

The vagus nerve strongly influences these autonomic functions including digestion, breathing, heart rate variability, and metabolic function and central nervous system (CNS) activity that affect mood, pain, stress management, sleep, and even memory and cognitive functions. The vagal influence over neurotransmitter release has been implicated in the regulation of inflammation and immune cell activity.

Here, we are using a non-invasive vagus nerve stimulator to monitor changes in cognitive function and other symptoms in people with IDD, both with and without ASD. The device is FDA-approved for migraine and cluster headaches in people 12 years and older. VNS activates the vagus nerve with mild electrical stimulation through the skin.

Rather than embarking on a rigorously designed study, we will conduct a series of single-subject studies that reflects each participant's symptoms. We will select the most appropriate dependent variables based on each person's symptom presentation.

03

Conditions studied

  • Autism Spectrum Disorder
  • Intellectual Disability
  • Autonomic Nervous System
  • Developmental Disability

Keywords

  • Vagus Nerve Stimulation
04

Who can participate

Ages eligible
12 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Children and adults aged 12-40 with intellectual and developmental disability (IDD) and/or autism spectrum disorder (ASD). Participants who are decisionally-impaired will be eligible with assent.
  2. Able to tolerate wearing an Apple Watch, EEG, and sit for a neurocognitive test
  3. Be on a stable dose of psychotropic medication for at least one month prior to enrollment
  4. Agree not to initiate new or change existing medications or behavior intervention

Exclusion criteria

Exclusion Criteria:

  1. Have an active implantable medical device (e.g., pacemaker, implanted hearing aid, etc.) or a metallic device, such as a stent, bone plate, or bone screw
  2. Have a comorbid physical or psychiatric disorder which would disrupt ability to tolerate vagal stimulation or comply with study demands (e.g., insulin dependent diabetes, bipolar, etc.)
  3. Vagus nerve lesion, damage, or structural abnormality (e.g., lymphadenopathy, neoplasm, previous surgery), or pain (e.g., dysesthesia, neuralgia and/or cervicalgia)
  4. Current or past history of neurological disorders or trauma, including uncontrolled epilepsy and head injury.
  5. Current or recent (within 12 months) participation in a clinical trial of a drug or a medical device.
  6. Use of drugs (within 4 weeks) that affect the autonomic nervous system (beta blockers, beta stimulant, etc.).
  7. Use of marijuana (including medical marijuana) for any indication
  8. Any condition per the investigators' clinical judgment that precludes participation in the study (e.g., pregnancy).
  9. Lack of capacity to consent and without a legally authorized representative (LAR) who is a parent, spouse, or an adult child.
  10. Living in a residential program (e.g., group home)
  11. Wards of state
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Vagus Nerve Stimulation (VNS)

    Single-subject design: ABA, ABBA, or ABBBA This study allows for a flexibility in the duration of research participation depending on one's response. The participant will be able to select one of the three design options (1, 2, or 3 months of VNS twice per day) in consultation with the study staff. That is, after the initial 1-month trial of VNS, the participant may choose to extend the VNS two more times (i.e., 1 or 2 months), for a total of 90 days.

    Device: Vagus Nerve Stimulation

Interventions

  • DeviceVagus Nerve Stimulation

    Vagal nerve stimulation (VNS) involves the use of a device to stimulate the vagus nerve with electrical impulses twice per day (AM \& PM) for two minutes each. It is an approved treatment for treatment resistant epilepsy and depression.

    Also known as: gammaCore

06

What researchers measure

Primary outcomes

  1. Aberrant Behavior Checklist-Community (ABC-C)

    The ABC-C is a 58-item questionnaire consisting of five subscales: Irritability, Lethargy, Inappropriate Speech, Hyperactivity, and Stereotypy. Minimum score = 0, maximum score = 174. Higher scores indicate more severity.

    Time frame: Change measured once per month for 3, 4, or 5 months

  2. Pervasive Developmental Disorder Behavior Inventory (PDDBI)

    The PDDBI is an informant-based assessment that examines treatment effectiveness and differentiates ASD from other conditions. It consists of the following Approach/Withdrawal Problems: 1) Sensory/Perceptual Approach, 2) Ritualisms/Resistance to Change, 3) Social Pragmatic, 4) Semantic Pragmatic, 5) Arousal Regulation, 6) Specific Fears, 7) Aggressiveness. Under Receptive/ Expressive Social Communication Abilities, there are 1) Social Approach Behaviors, 2) Expressive Language, and 3) Learning, Memory, and Receptive Language. Higher T scores on Approach/Withdrawal Problems indicate more symptom severity and higher T scores on Receptive/Expressive Social Communication indicate more skills.

    Time frame: Change measured once per month for 3, 4, or 5 months

  3. Behavior Rating Inventory of Executive Function (BRIEF)

    The BRIEF is an informant-based assessment that contains 63 (preschool age) 86 (school age) items with eight subdomains of executive function: 1) Inhibit, 2) Shift, and 3) Emotional Control subdomains together result in an additional composite Behavioral Regulation Index. The subdomains 4) Initiate, 5) Working Memory, 6) Plan/Organize, 7) Organization of Materials, and 8) Monitor provide a composite Metacognition Index. The indexes are also combined to obtain an overall Global Executive Composite. Higher T scores indicate more symptom severity.

    Time frame: Change measured once per month for 3, 4, or 5 months

  4. The Symptom Checklist-90-Revised (SCL-90-R)

    The SCL-90-R is a questionnaire designed to evaluate a broad range of psychological problems and symptoms of psychopathology. It is also useful in measuring treatment outcomes. Higher T scores indicate more symptom severity.

    Time frame: Change measured once per month for 3, 4, or 5 months

  5. Repetitive Behavior Scale-Revised (RBS-R)

    The RBS-R is a 44-item questionnaire that is used to measure the breadth of repetitive behavior in people with ASD. The RBS-R consists of six subscales including: Stereotyped, Self-injurious, Compulsive, Routine, Sameness, and Restricted Behaviors. Minimum score = 0; maximum score = 136. Higher scores indicate more severity.

    Time frame: Change measured once per month for 3, 4, or 5 months

  6. Yale-Brown Obsessive Compulsive Scale (Y-BOCS) (Y-BOCS)

    The Y-BOCS is a measurement tool for OCD. It is not a diagnostic tool. Rather, it is a scale used to gauge the severity and nature of OCD symptoms and to monitor improvement. Higher scores indicate severity. Minimum score = 0; maximum score = 40. Higher scores indicate more severity.

    Time frame: Change measured once per month for 3, 4, or 5 months

Secondary outcomes

  1. Neurocognitive assessment

    An online tablet-based nonverbal (i.e., visually presented on an iPad) neurocognitive tasks to examine specific components of cognition, particularly those associated with executive function skills related to frontal and medial temporal regions of the brain (e.g., planning, episodic memory, processing speed) will be collected. Subtests are specifically selected for IDD/ASD and graded in difficulty, minimizing floor and ceiling effects.

    Time frame: Change measured once per month for 3, 4, or 5 months

  2. Electro-encephalogram (EEG)

    EEG is a non-invasive test that records electrical activity in the brain. It works by picking up brain waves via electrodes that are attached to the scalp. EEG data will be collected for 10-15 mins while the participant is awake. Power, sample entropy, Lyapunov exponent, detrended fluctuation analysis, correlation dimension, and recurrence quantitative analysis (RQA) values on all frequency bands (delta, theta, alpha, beta, gamma, and gamma+) will be computed using a portable headset.

    Time frame: Change measured once per month for 3, 4, or 5 months

  3. Biorhythmic motion measurements

    On-body sensors: Patterns of motor and heart variability in the form of time series collected to align the signals for before, during, and after VNS comparison. OFF-body sensors: Time series of digital data to extract patterns of variability and stochastic signatures aligned to the stimulation.

    Time frame: Change measured once per month for 3, 4, or 5 months

Other outcomes

  1. Non-verbal Pain Measure

    Non-verbal Pain and Discomfort Indicators for those participants who are non-verbal. Minimum score = 0; maximum score = 8. Higher scores indicate more pain and discomfort.

    Time frame: Twice per day for 3, 4, or 5 months

  2. Columbia-Suicide Severity Rating Scale (C-SSRS)

    C-SSRS is a suicidal ideation and behavior rating scale to evaluate suicide risk. It rates one's degree of suicidal ideation on a scale, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent and behaviors." An answer of "yes" to any of the six questions may indicate a need for referral and an answer of "yes" to questions 4, 5 or 6 indicate high-risk.

    Time frame: every 4 weeks for 3, 4, or 5 months

  3. Clinical Global Impression Scale Severity & Improvement (CGI-S, CGI-I)

    measures of symptom severity, treatment response and the efficacy of treatments. Minimum score = 1; maximum score = 7. Higher scores indicate more severity (CGI-S) or worsening (CGI-I).

    Time frame: Change measured once per month for 3, 4, or 5 months

07

Study locations

2 sites
  • New York State Psychiatric Institute
    New York, New York 10032, United States
  • New York State Institute for Basic Research
    Staten Island, New York 10314, United States
08

References and documents

Individual participant data

Plan to share: No — Study withdrawn.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2025; primary completion for Dec 2027, 31 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2023
First posted
Feb 14, 2024
StartEst.
May 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06259201
Lead sponsor
New York State Institute for Basic Research
Responsible party
Sponsor
First posted
Feb 14, 2024
Start date
May 2025 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Feb 13, 2026

Study contacts

Helen Yoo, Ph.D.
principal investigator · New York State Institute for Basic Research

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion